Early Stage Breast Cancer Research Studies

Neoadjuvant trials

- **ptDNA/Liquid tumor biopsy**
  To determine if it is possible to use blood samples to predict response to treatment in breast cancer patients receiving preoperative (or neoadjuvant) therapy.
  https://clinicaltrials.gov/ct2/show/NCT02743910

- **ALTERNATE: neoadjuvant endocrine therapy, Stage II-III**
  To determine whether neoadjuvant endocrine therapy with Fulvestrant or the combination of Anastrozole and Fulvestrant is more effective than Anastrozole alone when given before surgery.
  https://clinicaltrials.gov/ct2/show/NCT01953588

- **Lymph node study**
  A trial to evaluate the role of axillary lymph node dissection and radiation therapy after chemotherapy.
  https://clinicaltrials.gov/ct2/show/NCT01901094

Adjuvant trials

- **PALLAS: Palbociclib & endocrine vs endocrine alone**
  To compare 5 years endocrine therapy with 2-year Palbociclib treatment **versus** at least 5 years endocrine therapy alone in patients with histologically confirmed Hormone Receptor Positive/HER2 negative invasive early breast cancer.
  https://clinicaltrials.gov/ct2/show/NCT02513394

- **BWEL: Weight loss in locally advanced BC after completion of SOC**
  A trial to determine if losing weight may help prevent breast cancer from coming back (recurring).
  https://clinicaltrials.gov/ct2/show/NCT02750826

- **ABC**
  A trial to determine if ASA is beneficial after standard therapy.
  https://clinicaltrials.gov/ct2/show/NCT02927249

- **S1418: Pembrolizumab vs placebo in TNBC patients**
  A Pembrolizumab immunotherapy trial for triple negative breast cancer patients with residual disease after chemotherapy.
  https://clinicaltrials.gov/ct2/show/NCT02954874
• **RU011501**: adjuvant GM-CSF vaccination for triple negative
An immunotherapy trial for triple negative breast cancer patients using a vaccine following standard therapy.
https://clinicaltrials.gov/ct2/show/NCT02593227
Anticipated to open at Inova Fall 2017

• **OLYMPIA: Olaparib in patients with BRCA+ mutations**
An Olaparib trial for HER2 negative patients with a BRCA mutation.
https://clinicaltrials.gov/ct2/show/NCT02032823

---

### Inova Breast Cancer Research Contact Information:

**Research Team:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mary J. Wilkinson, MD</td>
<td>Parisa Saifollahi, RN</td>
</tr>
<tr>
<td>David M. Heyer M.D.</td>
<td>Joshelynn Asis, RN</td>
</tr>
<tr>
<td>Kathleen K. Harnden, MD</td>
<td>Natalia Girard, B.S. CCRC</td>
</tr>
<tr>
<td>Margaret S. Howard, MD</td>
<td>Neva Kassis, B.S.</td>
</tr>
</tbody>
</table>

**Inova Breast Cancer Research**

Main Clinic: (703) 720-5210

Inova Breast Cancer Email: breastcancerresearch@inova.org

General Clinical Trial Information: https://clinicaltrials.gov/

https://www.breastcancertrials.org